Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes
Open accessAbstract
With the emphasis on intensive management of type 1 diabetes, data from studies support frequent monitoring of glucose levels to improve glycemic control and reduce glucose variability, which can be related to an increase in macro and microvascular complications. However, few perform capillary blood glucose that frequently. There are currently two available alternatives that this review will discuss, continuous glucose monitoring (CGM) and flash glucose monitoring. CGM has become an important diagnostic and therapeutic option in optimizing diabetes management. CGM systems are now more accurate, smaller, and easier to use compared to original models. Randomized controlled trials (RCTs) have demonstrated that CGM can improve Hemoglobin A1c (HbA1C) and reduce glucose variability in both continuous subcutaneous insulin infusion and multiple daily injection users. When used in an automated “insulin-suspend” system, reduced frequency of hypoglycemia and shorter time spent in hypoglycemic range have been demonstrated. Despite the potential benefits CGM has to offer in clinical practice, concerns exist on the accuracy of these devices and patient compliance with therapy, which may prevent the true clinical benefit of CGM being achieved, as observed in RCTs. Flash glucose monitoring systems FreeStyle ® Libre™ (Abbott Diabetes Care, Alameda, CA) are as accurate as many CGM systems available and have the added benefit of being factory calibrated. Studies have shown that flash glucose monitoring systems are very well tolerated by patients and effectively reduce glucose variability, increasing time in range.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CGM use helps people with T1D achieve target time in range and avoid hyper- and hypoglycemia.
“The key benefits of CGM include real-time data monitoring for people with T1D and access for them and their HCPs to complete glucose datasets17; both of which help people to achieve their target time spent within the acceptable range (time in range [TIR]: 3.9–10.0 mmol/L [70–180 mg/dL]) and avoid hyper- and hypoglycemia.18”
From Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen (2020) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 39 · Cited by 87
Research works printed but not linked: 1
- Juvenile Diabetes Research Foundation Continuous Glu- cose Monitoring Study Group, Beck RW, Hirsch IB, et al.: Glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378-1383.
- Authors
- Slattery, D., & Choudhary, P.
- Affiliations
- King's College London (GB)
- ORCID
- Choudhary, Pratik
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-05
- Volume
- 19
- Issue
- 2_suppl
- Pages
- S55-S61
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- PMC
- PMC5444504
- OpenAlex
- W2620033650
- Cited by
- 87
- References
- 39
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 4 · 2023: 7 · 2022: 11 · 2021: 9 · 2020: 20 · 2019: 9 · 2018: 12 · 2017: 4
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Technology & Therapeutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, flash glucose monitoring, type 1 diabetes, glycemic control, glycemic variability, HbA1c, hypoglycemia, insulin pump therapy, multiple daily insulin injections, device accuracy, medication adherence, time in range, FreeStyle Libre
- MeSH terms
- Data Accuracy, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Blood Glucose Self-Monitoring, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review